Early antibody treatment significantly reduces hospitalization and death in high-risk Covid-19 patients
In short: A phase 3 clinical trial found that the monoclonal antibody sotrovimab significantly lowered the risk of severe disease progression in high-risk patients with symptomatic Covid-19. Researchers observed that patients receiving the antibody early in their illness were much less likely to require hospitalization or die within 29 days compared to those given a placebo.
The study aimed to determine if sotrovimab could prevent Covid-19 from worsening in older adults or those with underlying conditions. By comparing 291 patients receiving the antibody to 292 receiving a placebo, the team found an 85% relative risk reduction in severe outcomes.
The trial was a double-blind, multicenter study involving nonhospitalized patients within five days of symptom onset. A limitation of this specific finding is that it represents a prespecified interim analysis of an ongoing trial.
Why it matters: Early antibody treatment can be an effective tool for preventing severe outcomes in vulnerable populations with Covid-19.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Gupta et al. (2021). Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. New England Journal of Medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-early-antibody-treatment-significantly-reduces-hospitalizati.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Pandemics & epidemics · More in Health · Latest · A–Z · All topics
